959466-51-4

Basic information

• Product Name: 2,4-Bis(benzyloxy)-5-isopropylbenzaldehyde
• Synonyms: 2,4-Bis(benzyloxy)-5-isopropylbenzaldehyde;2,4-Bis(Benzyloxy)-5-Isopropylbenzaldehyde(WXC04809)
• CAS NO: 959466-51-4
• Molecular Formula: C₂₄H₂₄O₃
• Molecular Weight: 360.44556
• Mol File: 959466-51-4.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 529.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.124
• CAS DataBase Reference: 2,4-Bis(benzyloxy)-5-isopropylbenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Bis(benzyloxy)-5-isopropylbenzaldehyde(959466-51-4)
• EPA Substance Registry System: 2,4-Bis(benzyloxy)-5-isopropylbenzaldehyde(959466-51-4)

Safety Data

• Hazardous Substances Data: 959466-51-4(Hazardous Substances Data)

Usage

General Description

2,4-BIS(Benzyloxy)-5-ISOPROPYLBENZALDEHYDE is a chemical compound with the molecular formula C27H28O3. It is a benzaldehyde derivative and is commonly used as a fragrance and flavoring agent in various consumer products. This chemical is known for its sweet, floral scent and is often used in perfumes, cosmetics, and other personal care products. It is also used in the production of pharmaceuticals and as a chemical intermediate in the synthesis of other compounds. Additionally, it is utilized in the manufacturing of specialty chemicals and fine chemicals for various industrial applications. However, it is important to handle this compound with care as it may pose health and safety risks if not used properly.

Upstream product

• 1155371-80-4 (((4-isopropyl-1,3-phenylene)bis(oxy))bis(methylene))dibenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 100-39-0 benzyl bromide 
• 1155371-78-0 2-(2,4-bis(benzyloxy)phenyl)propan-2-ol 
• 23504-03-2 2,4-dihydroxy-1-isopropylbenzene 
• 747414-16-0 (((4-(prop-1-en-2-yl)-1,3-phenylene)bis(oxy))bis(methylene))dibenzene 
• 958888-27-2 5-isopropyl-2,4-dihydroxy benzaldehyde 
• 100-44-7 benzyl chloride 

Relevant articles and documents

Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo

A series of ring-opened dihydroxybenzamides have been designed and synthesized as heat shock protein 90 inhibitors. One of derivatives, compound 6b ((N-ethyl-2,4-dihydroxy-5-isopropyl-N-(pyridin-3-yl)benzamide)) demonstrated remarkable antiproliferative activity against in human KRAS mutant A549 and EGFR T790 M mutant H1975 lung cancer cell lines with GI50 values of 0.07 and 0.05 μM, respectively. It is also active against in other cancer cell lines, such as colorectal HCT116 (GI50 = 0.09 μM), liver Hep3B (GI50 = 0.20 μM) and breast MDA-MB-231 (GI50 = 0.09 μM), and shows no evidence of toxicity in normal cell line. Compound 6b has an IC50 of 110.18 nM in HSP90α inhibitory activity, slightly better than reference compound 1 (17-AAG, IC50 = 141.62 nM) and achieves the degradation of multiple HSP90 client proteins in a dose- and time-dependent manner and downstream signaling of Akt in a concentration- and time-dependent manner in the human A549 lung cancer cell line. In the Boyden chamber assay, compound 6b can efficiently inhibit the migration of A549 cells when compared to the reference compound 1. It also induce significant activity through the apoptotic pathway. Treatment with 6b showed no vision toxicity (IC50 > 10 μM) on 661w photoreceptor cells as compared to AUY922 (3a) with a 0.04 μM values of IC50 and has no effect in hERG test. In a bidirectional Caco-2 permeability assay, compound 6b was classified as a highly permeable compound which is not a substrate of efflux transporters. In a pharmacokinetic study in rats, 6b showed an F = 17.8% of oral bioavailability. The effect of metabolic stability of compound 6b in human hepatocytes showed a T1/2 of 67.59 min. Compound 6b (50 mg/kg, po, daily) exhibits antitumor activity with a 72% TGD (tumor growth delay) in human A549 lung xenograft. The combination of 6b and afatinib, orally administered, showed tumor growth suppression with 67.5% of TGI in lung H1975 xenograft model. Thus compound 6b is a lead compound for further development of potential agents to treat lung cancer.

A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy

Therapeutic effects of photodynamic therapy (PDT) are limited by the selectivity of photosensitizer (PS). Herein, a novel tumor-targeted drug-PS conjugate (Gan-ZnPc) which integrated with zinc phthalocyanine (ZnPc) and Ganetespib has been developed. ZnPc is a promising PS with remarkable photosensitization ability. Ganetespib is a heat shock protein 90 (Hsp90) inhibitor with preferential tumor selectivity and conjugated to ZnPc as a tumor-targeted ligand. The multifunctional small molecule conjugate, Gan-ZnPc, could be bound to extracellular Hsp90 and then selectively internalized into the tumor cells, followed by the generation of abundant intracellular reactive oxygen species (ROS) upon irradiation. Besides, Gan-ZnPc can arrest cell proliferation and induce apoptosis by the inhibition of Hsp90. Herein, with combination of the inhibition of Hsp90 and the generation of cytotoxic ROS, Gan-ZnPc implements tumor selectivity, concentrated PDT and chemotherapy in a synergistic manner, which results in highly effective anti-tumor activity in vitro and in vivo.

Triazole derivative having HSP90 (Heat Shock Protein) inhibiting activity, as well as preparation method and application of triazole derivative

The invention discloses a triazole derivative having an HSP90 (Heat Shock Protein) inhibiting activity, as well as a preparation method and an application of the triazole derivative. Specifically, the invention relates to the triazole derivative having a structure as shown in a formula (I), a stereisomer of the triazole derivative and a pharmaceutically acceptable salt, wherein the definition of each substituent group in the formula (I) and the definition in a description are the same. The compound with a novel structure has the HSP90 inhibiting activity, can be used to cure cancers, neurodegenerative disorders, inflammation diseases, autoimmune diseases, ischemic brain injuries and the like, and has a broad application prospect.